Table 3.
Overall 1-year, 3-year, and 5-year net survival (%) of patients with sinonasal cancer according to selected risk factors, Lombardy SNC registry, 2008–2020. Follow-up, 2008–2023.
| Variable | 1-Year (95% CI) a | 3-Year (95% CI) a | 5-Year (95% CI) a |
|---|---|---|---|
| All patients | 79 (76–82) | 62 (59–66) | 57 (53–61) |
| Gender | |||
| Male | 79 (76–83) | 63 (59–68) | 59 (54–64) |
| Female | 77 (72–83) | 62 (56–68) | 53 (47–60) |
| Age | |||
| 0–49 | 85 (78–92) | 67 (59–76) | 59 (51–69) |
| 50–69 | 86 (82–90) | 71 (66–76) | 65 (60–71) |
| 70+ | 71 (66–76) | 55 (49–61) | 50 (43–57) |
| Period of diagnosis | |||
| 2008–2012 | 78 (73–83) | 62 (56–68) | 57 (51–63) |
| 2013–2016 | 79 (73–85) | 61 (55–69) | 55 (48–64) |
| 2017–2020 | 79 (74–84) | 64 (58–71) | 58 (51–67) |
| Cancer site (ICD-10 code) | |||
| Nasal cavity (C30.0) | 81 (76–86) | 69 (63–75) | 65 (58–72) |
| Paranasal sinuses (C31) | 77 (73–81) | 59 (54–64) | 52 (47–58) |
| Cancer morphology | |||
| Squamous cell carcinoma and variants | 80 (76–85) | 65 (60–71) | 60 (54–66) |
| Adenocarcinoma | 84 (80–89) | 71 (65–77) | 64 (57–71) |
| Neuroendocrine carcinoma | 74 (59–93) | 32 (19–56) | 29 (16–54) |
| Other epithelial neoplasm b | 64 (55–75) | 41 (31–53) | 39 (29–51) |
CI, confidence interval; ICD-10, International Classification of Diseases, Tenth Edition. a From Pohar Perme estimation. b Sinonasal undifferentiated carcinoma (SNUC) and not-otherwise-specified (NOS) carcinoma.